Endo to Buy Nupathe for $105M

Endo Health Solutions (NASDAQ:ENDP) today announced it has entered into an agreement under which Endo will acquire NuPathe Inc. (NASDAQ: PATH) for $2.85 per share in cash, or approximately $105 million.
As quoted in the press release:

Endo expects meaningful cost synergies from the transaction, which is expected to be accretive to Endo’s adjusted diluted earnings per share within the first 12 months of closing. 
ZECUITY, which was approved by the U.S. Food and Drug Administration (FDA) in January 2013 for the acute treatment of migraine with or without aura in adults, is the first and only FDA-approved prescription migraine patch. 

Read the full press release by Endo Health Solutions (NASDAQ:ENDP)  and Nupathe Inc (NASDAQ: PATH)